When was Propanc founded?

Propanc was founded in 2010 and raised its 1st funding round 2 years after it was founded.

Where is Propanc located?

Propanc is headquartered in Camberwell, Australia.

How many employees does Propanc have?

As of Sep 30, 2026, the latest employee count at Propanc is 4.

Is Propanc a funded company?

Propanc is a funded company, having raised a total of $30K across 15 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 24, 2012.

When was the latest funding round of Propanc?

Propanc's latest funding was a $***** Post IPO round on Nov 10, 2025, with participation from 0 investor. Its primary sector is Oncology. In Australia, the Oncology sector has seen $329M in funding in 2026 to date.

Where does Propanc rank among its competitors?

Propanc ranks 571st amongst 3460 active competitors, of which 1128 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Propanc?

Propanc's top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

Propanc - 2026 Company Profile, Team, Funding, Competitors & Financials

Propanc is a public company based in Camberwell (Australia), founded in 2010. It operates as a Developer of proenzyme-based cancer therapeutics. Propanc has raised $30K in funding. The company has 3460 active competitors, including 1128 funded and 793 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.

Company Details

Developer of proenzyme-based cancer therapeutics. It offers formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Their products involve or employ proenzymes, which are inactive precursors of enzymes. In the near term, they intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In future, they intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening.

Key Metrics

Founded Year

2010

Location

Camberwell, Australia

Stage

Public

Total Funding

$30K in 15 rounds

Latest Funding Round

Post IPO, Nov 10, 2025, $*****

Investors

Magna & 1 more

Ranked

571^st among 3460 active competitors

Employee Count

4 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3040 more

Exit Details

Public

View Propanc's full profile

Propanc is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
PROPANC BIOPHARMA, INC. CIN: 1517681 , United States, Active	Nov 22, 2010	-	-	-

Propanc got listed on Nov 12, 2012.

Click here to take a look at Propanc's IPO in detail

Propanc has raised a total funding of $30K over 15 rounds. Its first funding round was on May 24, 2012. Propanc has 2 institutional investors.

Here is the list of recent funding rounds of Propanc:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 10, 2025	8004602	Post IPO	4715065	2160611	1173914	8126155
Oct 20, 2023	2975174	Post IPO	9211496	2448804	8959209	6568537
Aug 30, 2023	1418739	Post IPO	2011163	1250020	5748172	7753241

Access funding benchmarks and valuations. Sign up today!

View details of Propanc's funding rounds and investors

Propanc's employee count trend

Propanc has 4 employees as of Sep 26. Here is Propanc's employee count trend over the years:

Uncover Propanc's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Propanc include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Propanc, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Relay Therapeutics 2016, Cambridge (United States), Public	Developer of drug discovery platform and study protein motion	$520M	BVF Partners, SoftBank Vision Fund & 17 others	71/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
9th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	72/100
571st	Propanc 2010, Camberwell (Australia), Public	Developer of proenzyme-based cancer therapeutics	$30K	Magna & 1 others	50/100